Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Department of Blood Transfusion, The Second Xiangya Hospital of Central South University, Changsha, China.
Cardiovasc Ther. 2022 Apr 9;2022:2950055. doi: 10.1155/2022/2950055. eCollection 2022.
Association between abdominal obesity and development of heart failure (HF) with preserved ejection fraction (HFpEF) between the sexes is not completely understood.
This study evaluated the association between abdominal obesity and the risk of all-cause mortality in patients with HFpEF while performing a gender outcome comparison.
A post hoc analysis was undertaken from the American cohort of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT). The primary outcome (all-cause mortality) and the secondary outcomes (cardiovascular mortality, hospitalization for HF, stroke, and MI) were evaluated via Cox proportional hazards models to compare the hazard ratios (HRs) between sexes in HFpEF patients. Abdominal obesity was defined as a waist circumference of ≥102 cm in men and ≥88 cm in women.
A total of 3320 HFpEF patients (1620 men [48.80%] and 1700 women [51.20%]) were included in the analysis. The mean follow-up period was 3.4 ± 1.7 years, with 503 patients dying during that time. After multivariable adjustment, abdominal obesity was significantly associated with an increased risk of all-cause mortality in males (adjusted HR: 1.32; 95% confidence interval [CI]: 1.02 to 1.71; = 0.038). Abdominal obesity was associated with hospitalization for HF in both male (adjusted HR: 1.39; 95% CI: 1.01 to 1.93; = 0.045) and female patients (adjusted HR: 1.15; 95% CI: 1.18 to 3.28; = 0.010).
Abdominal obesity is associated with increased risks of all-cause mortality in the male but not the female HFpEF population and is associated with increased risks of hospitalization for HF in both sexes.
男女之间腹部肥胖与射血分数保留的心力衰竭（HFpEF）发展之间的关联尚不完全清楚。
本研究评估了腹部肥胖与 HFpEF 患者全因死亡率风险之间的关联，并进行了性别结局比较。
从治疗保留心脏功能的心力衰竭伴醛固酮拮抗剂（TOPCAT）的美国队列中进行了一项事后分析。主要结局（全因死亡率）和次要结局（心血管死亡率、HF 住院、卒中和 MI）通过 Cox 比例风险模型进行评估，以比较 HFpEF 患者中男女之间的危险比（HR）。腹部肥胖定义为男性腰围≥102cm，女性腰围≥88cm。
共纳入 3320 例 HFpEF 患者（男性 1620 例[48.80%]，女性 1700 例[51.20%]）进行分析。平均随访时间为 3.4±1.7 年，在此期间有 503 例患者死亡。经多变量调整后，腹部肥胖与男性全因死亡率增加显著相关（调整后的 HR：1.32；95%置信区间[CI]：1.02 至 1.71； = 0.038）。腹部肥胖与男性（调整后的 HR：1.39；95% CI：1.01 至 1.93； = 0.045）和女性 HFpEF 患者（调整后的 HR：1.15；95% CI：1.18 至 3.28； = 0.010）HF 住院均相关。
腹部肥胖与男性而非女性 HFpEF 人群全因死亡率增加相关，并与两性 HF 住院风险增加相关。
